IP Library › Granted Patent US 8,916,534
Granted Patent B2
US 8,916,534 · App. 13/877,968 · Granted Dec 23, 2014

Methods of inducing insulin production

Inventor: Pal Saetrom (Trondheim, NO)
Assignee: Mina Therapeutics Limited
C12N15/1138C12N2310/11C12N15/1135C12N2310/14C12N2310/113C12N15/11C12N15/113
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,916,534
App. No.
13/877,968
Granted
Dec 23, 2014
Kind
B2
Abstract

The present invention provides a method of inducing insulin production in a cell by up-regulating a target gene involved in insulin production in said cell using an saRNA (short activating ribonucleic acid) which specifically down-regulates a target antisense RNA transcript present in said cell, wherein (i) said target RNA transcript is complementary to a sequence located on the coding strand of the target gene between 1000 nucleotides upstream and 1000 nucleotides downstream of the transcription start site of the target gene; and (ii) said sRNA is a single or double stranded RNA molecule up to 30 nucleotides in length comprising a sequence of at least 13 nucleotides which has at least 95% complementarity to a region of the target transcript. Also provided are certain saRNA molecules and uses thereof, particular medical uses, and induced cells and uses thereof.

Claims (4)

1. A short activating ribonucleic acid (saRNA) which upregulates PDX1 expression in a cell, said saRNA having a first strand consisting of (i) a sequence selected from SEQ ID NO: 15, 16, 17, and 18; and (ii) a 3′ tail formed of 1-5 uracils.

2. An saRNA according to claim 1 , wherein said 3′ tail is formed of 2 uracils.

3. A pharmaceutical composition comprising one or more saRNAs which upregulate PDX1 expression in a cell, selected from saRNAs having a first strand consisting of (i) a sequence selected from SEQ ID NO: 15, 16, 17 and 18; and (ii) a 3′ tail formed of 1-5 uracils.

4. A pharmaceutical composition according to claim 3 , wherein said 3′ tail of said saRNA is formed of 2 uracils.

Assignments (2)
SECURITY INTEREST Recorded Jan 30, 2023
From: MINA (HOLDINGS) LIMITED; MINA THERAPEUTICS LIMITED; MINA ALPHA LIMITED; MINA BETA LIMITED
To: BOOTSTRAP EUROPE 3.0 S.À R.L.
Reel/Frame 062547/0070 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2013
From: SAETROM, PAL
To: MINA THERAPEUTICS LIMITED
Reel/Frame 030826/0597 →
Priority Claims (2)
GB 1016989.4 · Oct 8, 2010 · national
GB 1103745.4 · Mar 7, 2011 · national
Continuity (1)
Related Publication 20130289258A1 · Oct 31, 2013